BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16266917)

  • 1. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
    Quach H; Januszewicz H; Westerman D
    Haematologica; 2005 Nov; 90 Suppl():ECR26. PubMed ID: 16266917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
    Petruskevicius I; Bukh A; Mertz H; Johnsen HE
    Ugeskr Laeger; 2008 Jun; 170(26-32):2350. PubMed ID: 18570771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
    Buckstein R; Patel H; Chesney A; Reis M; Imrie K
    Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
    Fietz T; Rieger K; Schmittel A; Thiel E; Knauf W
    Hematol J; 2004; 5(5):451-2. PubMed ID: 15448675
    [No Abstract]   [Full Text] [Related]  

  • 6. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
    Piro LD; Carrera CJ; Carson DA; Beutler E
    N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment for recurrent hairy cell leukemia].
    Al'-Radi LS; Pivnik AV; Zingerman BV; Kravchenko SK
    Ter Arkh; 2012; 84(7):4-9. PubMed ID: 23038964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of hairy cell leukemia variant with rituximab.
    Narat S; Gandla J; Dogan A; Mehta A
    Leuk Lymphoma; 2005 Aug; 46(8):1229-32. PubMed ID: 16085567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
    Robak T
    Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which role for rituximab in hairy cell leukemia? Reflections on six cases.
    Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T
    Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report.
    Hadzi-Pecova L; Stojanovik A; Petrusevska G; Panovska I
    Prilozi; 2008 Dec; 29(2):355-60. PubMed ID: 19259059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients.
    Marotta G; Frassoldati A; Zinzani P; Annino L; Brugiatelli M; Ambrosetti A; Lenoci M; Federico M; Foa R; Lauria F;
    Eur J Haematol; 2006 Aug; 77(2):109-13. PubMed ID: 16856905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL; Foà R
    Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab.
    Goldaniga M; Guffanti A; Gianelli U; Magni M; Lambertenghi Deliliers G; Baldini L
    Haematologica; 2004 Nov; 89(11):ECR41. PubMed ID: 15533846
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab.
    Hensel M; Ho AD
    Am J Hematol; 2003 May; 73(1):37-40. PubMed ID: 12701118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The disease with hope: hairy cell leukemia.
    Becker SE
    Clin J Oncol Nurs; 2007 Oct; 11(5):731-5. PubMed ID: 17962181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.